TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03077308

Intervention type: PROCEDURE
Intervention: Auditory and Visual Event-related Potentials and EEG
Description: Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.

Intervention type: PROCEDURE
Intervention: Auditory and Visual Event-related Potentials and EEG
Description: Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.

Intervention type: PROCEDURE
Intervention: Auditory and Visual Event-related Potentials and EEG
Description: Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.

Intervention type: PROCEDURE
Intervention: Auditory and Visual Event-related Potentials and EEG
Description: Specifically, through up to three standardized sessions (i.e., annual \[every 10-14 months\]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
Study: NCT02105857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: grade A+ knee mobilization
Description: grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
Study: NCT00709345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sessions
Description: Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-matched attention control sessions
Description: Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
Study: NCT00137280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Chronic Illness Care Model
Description: A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
Study: NCT04253678

Intervention type: DRUG
Intervention: Vortioxetine
Description: Flexible dosing from 5mg to 20mg based on attending psychiatrist's discretion
Study: NCT02178189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Calorie Infant formula
Description: Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Calorie Infant Formula
Description: Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
Study: NCT01057940

Intervention type: PROCEDURE
Intervention: DBE PEJ placement
Description: One time procedure with follow-up telephone call.
Study: NCT01823887

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: Electrical Stimulation of the Vagus Nerve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Description: Electrical Stimulation of the Vagus Nerve
Study: NCT01512173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol gel
Description: Topical administration twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration twice daily
Study: NCT02622594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic Acid (ALA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic Acid (ALA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic Acid (ALA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic Acid (ALA)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Environ Cosmetic Roller

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Environ Cosmetic Roller

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Environ Cosmetic Roller

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Environ Cosmetic Roller

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLU-U IIlluminator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLU-U IIlluminator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLU-U IIlluminator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLU-U IIlluminator
Study: NCT01204372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine - Trastuzumab - Erlotinib
Description: Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~* Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~* Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~* Erlotinib: oral route 100 mg/day from C1D1.
Study: NCT05362136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: perforation of the sinus floor
Description: perforation of the cortical layer of the sinus floor prior to inserting the augmentation material during sinus floor elevation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no perforation of the sinus floor
Description: standard procedure for sinus floor elevation
Study: NCT01312077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.

Intervention type: DRUG
Group type: OTHER
Intervention: Intrathecal morphine
Description: intrathecal morphine bolus 200 micrograms
Study: NCT03531567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mystic Isle Game
Description: 8 week virtual reality based exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Home Exercise Program
Description: 8 week standard occupational therapy home exercise program
Study: NCT03300453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2/5-hNAGLU
Description: one-time brain intraparenchymal gene therapy dose
Study: NCT01596205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot assisted cognitive training
Description: We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cognitive training group
Description: Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil.
Study: NCT00128206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 900 mg twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Rifampin 600mg once per day
Study: NCT03954171

Intervention type: OTHER
Group type: OTHER
Intervention: Patients treated with platinum based-chemotherapy
Description: Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~* before treatment initiation (blood sample),~* during hospitalisation for surgery (blood sample),~* during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.
Study: NCT00677144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OS (oxalipaltin+S-1)
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX (oxalipaltin+capecitabine)
Description: Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
Study: NCT02679066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sugar-tong splint
Description: Plaster immobilization including the elbow

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short forearm cast
Description: Fiberglass immobilization with elbow free
Study: NCT01364610

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bravo
Description: Bravo pH Monitoring System sited manometrically.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
Study: NCT01724606

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy (WBRT)
Description: WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
Study: NCT03421223

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03836638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 Units of botulinum toxin
Description: 30 Units of botulinum toxin to upper face

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 Units of botulinum toxin
Description: 30 Units of botulinum toxin to upper face

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 Units of botulinum toxin
Description: 50 Units of botulinum toxin to upper face
Study: NCT03438656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
Study: NCT02088580

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple Chronotherapy
Study: NCT04366544

Intervention type: OTHER
Group type: OTHER
Intervention: Part A2: Sample collection
Description: Blood and Stool

Intervention type: OTHER
Group type: OTHER
Intervention: Part A2: Sample collection
Description: Blood and Stool

Intervention type: OTHER
Group type: OTHER
Intervention: Part A2: Sample collection
Description: Blood and Stool

Intervention type: OTHER
Group type: OTHER
Intervention: Part B:
Description: EEG and fMRI

Intervention type: OTHER
Group type: OTHER
Intervention: Part B:
Description: EEG and fMRI
Study: NCT00834132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 600 mg Tablet
Description: 1 x 600mg, single-dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zithromax® 600 mg Tablet
Description: 1 x 600mg, single-dose fed
Study: NCT03075943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: InSea2
Description: Daily supplement: 2 capsules of InSea2

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplement: 2 capsules of Placebo
Study: NCT01155310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Helium/Oxygen 78%/22%
Description: The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Air/Oxygen
Description: The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices.
Study: NCT00712075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSST+PDA
Description: PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Social Skills Training
Description: Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PDA-only
Description: To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
Study: NCT02660346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Control Arm Treatment
Study: NCT01665495

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended pericardial drainage by catheter
Description: Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return\<30 ml.
Study: NCT02660346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: Study Arm Treatment
Study: NCT02792946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acebrophylline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acebrophylline
Study: NCT03686722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is used primarly in treatment of diabetes type II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is used primarly in treatment of diabetes type II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Daclatsvir is a direct acting antiviral drug
Study: NCT03004131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride + fluticasone propionate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate nasal spray + loratadine
Study: NCT01401205

Intervention type: OTHER
Intervention: upper airway ultrasonographic examination
Description: upper airway ultrasonographic examination and cuff leak test
Study: NCT02436200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
Study: NCT00186992

Intervention type: RADIATION
Group type: OTHER
Intervention: image-guided radiotherapy
Description: Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
Study: NCT01725308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Taken by mouth (orally).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Taken by mouth (orally).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Taken by mouth (orally).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Taken by mouth (orally).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Taken by mouth (orally).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken by mouth (orally).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Taken by mouth (orally).
Study: NCT00545948

Intervention type: DRUG
Group type: OTHER
Intervention: Vinorelbine followed by Cisplatin
Description: Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).

Intervention type: DRUG
Group type: OTHER
Intervention: Pemetrexed followed by Cisplatin
Description: Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
Study: NCT00675779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive (Mercilon)
Description: oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
Study: NCT04128228

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 8-week outpatient treatment
Description: Individuals with AUD participated in an 8-week treatment program integrating cognitive behavioral techniques focused on emotion regulation with breathing-based stress management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 8-week outpatient treatment
Description: Individuals with AUD participated in an 8-week treatment program integrating cognitive behavioral techniques focused on emotion regulation with breathing-based stress management.
Study: NCT03285893

Intervention type: OTHER
Intervention: oral cell DNA adducts
Description: oral cells will be collected, DNA isolated, and analyzed for adducts
Study: NCT00675779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin + oral contraceptive
Description: atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
Study: NCT02796547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Infiltration of the banks of the episiotomy done with Levobupivacaine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: Infiltration of the banks of the episiotomy done with physiological serum
Study: NCT01079858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 114657 (ORB Preserved Ocular Emulsion)
Description: Patients will dose as needed throughout the day (PRN) for 4 weeks.
Study: NCT04708691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: aerobic exercise